Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care
Pre-clinicalCompletedDevelopment Stage
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
Mar 10, 2022 → Sep 13, 2022
About Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care
Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care is a pre-clinical stage product being developed by Bayer for Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion. The current trial status is completed. This product is registered under clinical trial identifier NCT05236257. Target conditions include Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05236257 | Pre-clinical | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion